Mission awarded $5.2m to advance potential Parkinson’s treatment
The progressive neurodegenerative condition affects around 153,000 people in the UK
Read More
Tag: Mission Therapeutics
Mission Therapeutics concludes clinical assessment for lead DUB inhibitor
Safety, tolerability and pharmacokinetic endpoints for MTX652 have been successfully met
Read More
Mission Therapeutics launches clinical trial for kidney disease therapy
MTX652 has advanced through preclinical regulatory toxicology studies and is ready for a phase 1 trial
Read More
- Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
- Venner Shipley announces opening of new Bristol office
- AAX Biotech and Vascurie announce new neuro-oncology collaboration
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
